irsogladine has been researched along with Adamantiades-Behcet Disease in 1 studies
irsogladine: RN given refers to parent cpd; MN 1695 refers to maleate salt
| Excerpt | Relevance | Reference |
|---|---|---|
| "Irsogladine 2-4 mg/day was administered orally to ten BD patients (cases 1-10), three men and seven women, with a mean age of 48." | 2.73 | Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study. ( Kamatani, N; Kotake, S; Nanke, Y; Ogiuchi, H; Okamoto, T, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nanke, Y | 1 |
| Kamatani, N | 1 |
| Okamoto, T | 1 |
| Ogiuchi, H | 1 |
| Kotake, S | 1 |
1 trial available for irsogladine and Adamantiades-Behcet Disease
| Article | Year |
|---|---|
Irsogladine is effective for recurrent oral ulcers in patients with Behçet's disease : an open-label, single-centre study.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Behcet Syndrome; Cell Communication; Female; Follow- | 2008 |